The US Food and Drug Administration on Friday approved the first prescription medicine for obstructive sleep apnea: the ...

Zepbound, the new GLP-1 weight-loss drug from Eli Lilly & Co., has been approved by the Food and Drug Administration for ...

The Food and Drug Administration on Friday approved Eli Lilly’s anti-obesity drug Zepbound as the first ... Zepbound, similar ...

US regulators on Friday approved the first drug treatment for sleep apnea, permitting the use of a weight-loss medication for ...

Novo Nordisk has told the world it expects patients to lose “at least 25%” of their body weight on its experimental drug ...

The FDA on Friday approved Eli Lilly's weight-loss drug Zepbound as a treatment for moderate-to-severe sleep apnea and obesity.

Shares of Ozempic-maker Novo Nordisk were down more than 20% in recent trade as the Danish drugmaker headed for its worst day since the 1980s. The stock took a hit after a late-stage trial showed that ...

Over the past few months, Blue Cross Blue Shield of Michigan, the state’s largest insurer, has scaled back on coverage of the ...

Novo Nordisk’s latest attempt in weight loss, a combination drug called CagriSema, matched the bar set by Lilly’s currently ...

The federal government is phasing out off-brand copies of two blockbuster drugs used to treat obesity and diabetes.

Signs at AMPAC Fine Chemicals' location in the Petersburg Industrial Park have already been changed to 'Novo Nordisk' in advance of the acquisition ...